What the FDA labels say about taking them together
Clopidogrel and prasugrel
Prasugrel's FDA label of February 11, 2025 names clopidogrel in its contraindications section; the clopidogrel label PlainMeds reads does not name prasugrel. The prasugrel label: “With the dosing regimens used in TRITON-TIMI 38, TIMI Major and TIMI Minor bleeding events were more common on prasugrel tablets than on clopidogrel.”
Check it at the source: the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC); the prasugrel FDA label on DailyMed (effective February 11, 2025, Panacea Biotec Limited).
What does the clopidogrel label say about prasugrel?
Clopidogrel's label (effective May 30, 2025) does not name prasugrel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed
What does the prasugrel label say about clopidogrel?
Prasugrel label, contraindicationsIn TRITON-TIMI 38 ( TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic).
Prasugrel label, warnings and precautionsWith the dosing regimens used in TRITON-TIMI 38, TIMI (Thrombolysis in Myocardial Infarction) Major (clinically overt bleeding associated with a fall in hemoglobin ≥5 g/dL, or intracranial hemorrhage) and TIMI Minor (overt bleeding associated with a fall in hemoglobin of ≥3 g/dL but <5 g/dL) bleeding events were more common on prasugrel tablets than on clopidogrel [see Adverse Reactions (6.1)].
Source: FDA drug label (Effient, NDA022307), Cosette Pharmaceuticals, Inc., effective September 7, 2022 (SPL set 69ea2d58-5353-4222-b61f-cab976fa7e5e), via openFDA
Source: FDA drug label (PRASUGREL), Panacea Biotec Limited, effective February 11, 2025 (SPL set 944c195a-de24-a44c-8baa-84b624b5ddcb), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clopidogrel | Prasugrel | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Angina | Heart attack and coronary artery disease, Angina |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0472 per tablet 75 mg tablet | $0.263 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once